Blackstone Life Sciences

• Menu Column Tactical Opportunities Infrastructure Life Sciences Blackstone Growth Blackstone Energy Transition Partners
• Blackstone Energy Transition Partners
• Menu Column Who We Serve Institutional Clients Private Wealth Insurance
• Menu Column Transformation Portfolio Operations Technology and Innovations
• Menu Column An Integrated Approach to ESG Overview Diversity, Equity & Inclusion Blackstone Career Pathways™
• An Integrated Approach to ESG
• Diversity, Equity & Inclusion
• Menu Column Blackstone Charitable Foundation Overview
• Menu Column News View All Press Releases In the News BX Highlights Portfolio Spotlight
• Menu Column Insights View All Education Firm News Market Views Portfolio Insights

Blackstone Life Sciences (BXLS)

We combine scale capital with deep clinical development expertise to help advance innovative medicines and technologies with the potential to transform patients’ lives Our team invests across the life cycle of companies and products in a range of therapeutic areas

Medicines Brought to Market MDs or PhDs on the Team

We partner with pharmaceutical, biotech and medical technology companies to fund products that address unmet medical needs and have the potential to improve the quality of life for patients around the world.

Blackstone Life Sciences (BXLS) fills a critical void in the industry While the life sciences are seeing unprecedented innovation driven by rapid advancements in science and technology, there is a lack of funding necessary to bring medicines and healthcare technologies to market We invest in and partner with pharmaceutical, biotechnology and medical technology companies to help meet this need

BXLS combines clinical, commercial and operational expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise

We seek to deliver value for investors by focusing on areas where we can apply our deep clinical and commercial domain expertise By investing in promising candidates in late-stage development, we aim to make a positive impact on the most people with the lowest clinical risk

The Blackstone Life Sciences team of employees, Senior Advisors and Development Company personnel is responsible — both in its current capacity and prior experiences— for bringing 111 medicines to market in 17 different therapeutic areas.

In March 2022, Blackstone Life Sciences announced a partnership with Sanofi to advance the development of Sarclisa®, a promising treatment for patients with multiple myeloma (MM), a type of blood cancer The partnership will focus on developing a subcutaneous form of the treatment to make its delivery more convenient for patients with MM This partnership showcases the flexible capital and deep expertise that enables BXLS to partner with leading pharmaceutical companies to advance potentially lifesaving products

In April 2020, BXLS led a $2 billion strategic collaboration with Alnylam anchored around the acquisition of a royalty interest in inclisiran, an innovative product, which will potentially bring new benefits to patients with high cholesterol — a major risk factor for cardiovascular disease The drug began receiving regulatory approvals globally in the fall of 2021

Note: All figures as of December 31 2022, unless otherwise indicated

• Evaluate 2020 data and estimates and medicines brought to market by BXLS and development company employees and Senior Advisors (Nick Galakatos, Emmett Cunningham, Kurt Wheeler, Bob DeBenedetto, Barry Gertz, Dennis Henner, Ed Scolnick, Jeff Chodakewitz, Kiran Reddy, Francois Nader, Olivier Brandicourt) while they worked at prior employers The development of a medicine involves many professionals The degree of involvement by a given BXLS professional varies medicine to medicine Therefore, the performance shown reflects the contributions of a number of professionals and may not be indicative of any individual’s contributions to the transactions The number of developed medicines is measured when a drug is approved in any jurisdiction Senior Advisors are not employees of Blackstone

“We support promising companies and products, providing flexible capital and clinical expertise to advance innovation and improve outcomes for patients ” GLOBAL HEAD OF LIFE SCIENCES

Updates from Life Sciences

Big Bets on Biotech

Nick Galakatos, Global Head of Blackstone Life Sciences, discussed our “building-beaker-bedside” model at CNBC’s Healthy Returns Summit We invest in promising new treatments, real estate for critical research and logistics facilities to help innovative therapies reach patients faster